Upregulation of SOCS-3 and PIAS-3 impairs IL-12-mediated interferon-gamma response in CD56+ T cells in HCV-infected heroin users

PLoS ONE

Volumn 5, Issue 3, 2010, Pages

  Ye, Li ^a   Wang, Xu ^a   Metzger, David S ^b   Riedel, Eric ^c   Montaner, Luis J ^d   Ho, Wenzhe ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR; JANUS KINASE 2; PROTEIN INHIBITOR OF ACTIVATED STAT; PROTEIN INHIBITOR OF ACTIVATED STAT 3; PROTEIN KINASE TYK2; STAT1 PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG; CHAPERONE; DIAMORPHINE; PIAS3 PROTEIN, HUMAN; SOCS3 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING;

ADULT; ARTICLE; CELL FUNCTION; CELL ISOLATION; CELL STIMULATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS C; HEROIN DEPENDENCE; HUMAN; INNATE IMMUNITY; LIVER; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; T LYMPHOCYTE; UPREGULATION; VIRUS LOAD; BIOSYNTHESIS; CYTOLOGY; GENE EXPRESSION REGULATION; HEPATITIS C VIRUS; METABOLISM; MONONUCLEAR CELL; VIROLOGY;

HEPATITIS C VIRUS;

ANTIGENS, CD56; GENE EXPRESSION REGULATION, VIRAL; HEPACIVIRUS; HEPATITIS C; HEROIN; HEROIN DEPENDENCE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-12; LEUKOCYTES, MONONUCLEAR; LIVER; MOLECULAR CHAPERONES; PROTEIN INHIBITORS OF ACTIVATED STAT; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; T-LYMPHOCYTES; UP-REGULATION;

EID: 77949716895     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009602     Document Type: Article

References (54)

1. Day C, Ross J, Dolan K (2003) Hepatitis C-related discrimination among heroin users in Sydney: drug user or hepatitis C discrimination? Drug and Alcohol Review 22: 317-321.
2. Smyth BP, Barry J, Keenan E (2005) Irish injecting drug users and hepatitis C: the importance of the social context of injecting. International Journal of Epidemiology 34: 166-172.
3. Bassani S, Toro C, de la Fuente L, Brugal MT, Jimenez V, et al. (2004) [Rate of infection by blood-borne viruses in active heroin users in 3 Spanish cities]. Medicina Clinica 122: 570-572.
4. Garten RJ, Lai S, Zhang J, Liu W, Chen J, et al. (2004) Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. International Journal of Epidemiology 33: 182-188.
5. Backmund M, Meyer K, Wachtler M, Eichenlaub D (2003) Hepatitis C virus infection in injection drug users in Bavaria: risk factors for seropositivity. European Journal of Epidemiology 18: 563-568.
6. Quaglio G, Lugoboni F, Pajusco B, Sarti M, Talamini G, et al. (2003) Factors associated with hepatitis C virus infection in injection and noninjection drug users in Italy. Clinical Infectious Diseases 37: 33-40.
7. Williams I (1999) Epidemiology of hepatitis C in the United States. Am J Med 107: 2S-9S.
8. McCarthy JJ, Flynn N (2001) Hepatitis C in methadone maintenance patients: prevalence and public policy implications. Journal of Addictive Diseases 20: 19-31.
9. Edlin BR, Seal KH, Lorvick J, Kral AH, Ciccarone DH, et al. (2001) Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? New England Journal of Medicine 345: 211-215.
10. Oliveira ML, Bastos FI, Telles PR, Yoshida CF, Schatzmayr HG, et al. (1999) Prevalence and risk factors for HBV, HCV and HDV infections among injecting drug users from Rio de Janeiro, Brazil. Brazilian Journal of Medical and Biological Research 32: 1107-1114.
11. Sacerdote P, Gaspani L, Rossoni G, Panerai AE, Bianchi M (2001) Effect of the opioid remifentanil on cellular immune response in the rat. Int Immunopharmacol 1: 713-719.
12. Sacerdote P (2006) Opioids and the immune system. Palliat Med 20 Suppl 1: s9-15.
13. Vallejo R, de Leon-Casasola O, Benyamin R (2004) Opioid therapy and immunosuppression: a review. Am J Ther 11: 354-365.
14. Li Y, Ye L, Peng JS, Wang CQ, Luo GX, et al. (2007) Morphine inhibits intrahepatic interferon- alpha expression and enhances complete hepatitis C virus replication. J Infect Dis 196: 719-730.
15. Li Y, Zhang T, Douglas SD, Lai JP, Xiao WD, et al. (2003) Morphine enhances hepatitis C virus (HCV) replicon expression. Am J Pathol 163: 1167-1175.
16. Sharp BM, Roy S, Bidlack JM (1998) Evidence for opioid receptors on cells involved in host defense and the immune system. J Neuroimmunol 83: 45-56.
17. Homan JW, Steele AD, Martinand-Mari C, Rogers TJ, Henderson EE, et al. (2002) Inhibition of morphine-potentiated HIV-1 replication in peripheral blood mononuclear cells with the nuclease-resistant 2-5A agonist analog, 2-5A(N6B). J Acquir Immune Defic Syndr 30: 9-20.
18. Peterson PK, Sharp B, Gekker G, Brummitt C, Keane WF (1987) Opioidmediated suppression of interferon-gamma production by cultured peripheral blood mononuclear cells. J Clin Invest 80: 824-831.
19. Wang J, Barke RA, Charboneau R, Loh HH, Roy S (2003) Morphine negatively regulates interferon-gamma promoter activity in activated murine T cells through two distinct cyclic AMP-dependent pathways. J Biol Chem 278: 37622-37631.
20. Stoll-Keller F, Schmitt C, Thumann C, Schmitt MP, Caussin C, et al. (1997) Effects of morphine on purified human blood monocytes. Modifications of properties involved in antiviral defences. Int J Immunopharmacol 19: 95-100.
21. Schmidt RE, Murray C, Daley JF, Schlossman SF, Ritz J (1986) A subset of natural killer cells in peripheral blood displays a mature T cell phenotype. J Exp Med 164: 351-356.
22. Kelly-Rogers J, Madrigal-Estebas L, O'Connor T, Doherty DG (2006) Activation-induced expression of CD56 by T cells is associated with a reprogramming of cytolytic activity and cytokine secretion profile in vitro. Hum Immunol 67: 863-873.
23. Doherty DG, Norris S, Madrigal-Estebas L, McEntee G, Traynor O, et al. (1999) The human liver contains multiple populations of NK cells, T cells, and CD3+CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. J Immunol 163: 2314-2321.
24. Doherty DG, O'Farrelly C (2000) Innate and adaptive lymphoid cells in the human liver. Immunol Rev 174: 5-20.
25. Ohkawa T, Seki S, Dobashi H, Koike Y, Habu Y, et al. (2001) Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells. Immunology 103: 281-290.
26. Loza MJ, Metelitsa LS, Perussia B (2002) NKT and T cells: coordinate regulation of NK-like phenotype and cytokine production. Eur J Immunol 32: 3453-3462.
27. Jin Y, Fuller L, Carreno M, Esquenazi V, Tzakis AG, et al. (1998) The regulation of phenotype and function of human liver CD3+/CD56+ lymphocytes, and cells that also co-express CD8 by IL-2, IL-12 and anti-CD3 monoclonal antibody. Hum Immunol 59: 352-362.
28. Lu PH, Negrin RS (1994) A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 153: 1687-1696.
29. Kronenberg M (2005) Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 23: 877-900.
30. Vitale M, Caruso A, Licenziati S, Rodella L, Fiorentini S, et al. (2000) Differential production of IFN-gamma, analyzed at the single-cell level, by specific subsets of human NK and T cells from healthy and HIV(+) subjects. Cytometry 39: 189-194.
31. Golden-Mason L, Castelblanco N, O'Farrelly C, Rosen HR (2007) Phenotypic and functional changes of cytotoxic CD56pos natural T cells determine outcome of acute hepatitis C virus infection. J Virol 81: 9292-9298.
32. Deignan T, Curry MP, Doherty DG, Golden-Mason L, Volkov Y, et al. (2002) Decrease in hepatic CD56(+) T cells and V alpha 24(+) natural killer T cells in chronic hepatitis C viral infection. J Hepatol 37: 101-108.
33. Kawarabayashi N, Seki S, Hatsuse K, Ohkawa T, Koike Y, et al. (2000) Decrease of CD56(+)T cells and natural killer cells in cirrhotic livers with hepatitis C may be involved in their susceptibility to hepatocellular carcinoma. Hepatology 32: 962-969.
34. Okumura A, Ishikawa T, Maeno T, Sato K, Ayada M, et al. (2005) Changes in natural killer T cells subsets during therapy in type C hepatitis and hepatocellular carcinoma. Hepatol Res 32: 213-217.
35. Ye L, Wang X, Wang S, Wang Y, Song L, et al. (2009) CD56+ T cells inhibit hepatitis C virus replication in human hepatocytes. Hepatology 49: 753-762.
36. Byrnes AA, Li DY, Park K, Thompson D, Mocilnikar C, et al. (2007) Modulation of the IL-12/IFN-gamma axis by IFN-alpha therapy for hepatitis C. J Leukoc Biol 81: 825-834.
37. Trinchieri G (1998) Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 70: 83-243.
38. Watford WT, Hissong BD, Bream JH, Kanno Y, Muul L, et al. (2004) Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev 202: 139-156.
39. Eisen-Vandervelde AL, Waggoner SN, Yao ZQ, Cale EM, Hahn CS, et al. (2004) Hepatitis C virus core selectively suppresses interleukin-12 synthesis in human macrophages by interfering with AP-1 activation. J Biol Chem 279: 43479-43486.
40. Wormald S, Hilton DJ (2004) Inhibitors of cytokine signal transduction. J Biol Chem 279: 821-824.
41. Eyles JL, Metcalf D, Grusby MJ, Hilton DJ, Starr R (2002) Negative regulation of interleukin-12 signaling by suppressor of cytokine signaling-1. J Biol Chem 277: 43735-43740.
42. Yamamoto K, Yamaguchi M, Miyasaka N, Miura O (2003) SOCS-3 inhibits IL-12-induced STAT4 activation by binding through its SH2 domain to the STAT4 docking site in the IL-12 receptor beta2 subunit. Biochem Biophys Res Commun 310: 1188-1193.
43. Schmidt D, Muller S (2003) PIAS/SUMO: new partners in transcriptional regulation. Cell Mol Life Sci 60: 2561-2574.
44. Yoshimura A, Naka T, Kubo M (2007) SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 7: 454-465.
45. Vlotides G, Sorensen AS, Kopp F, Zitzmann K, Cengic N, et al. (2004) SOCS-1 and SOCS-3 inhibit IFN-alpha-induced expression of the antiviral proteins 2,5-OAS and MxA. Biochem Biophys Res Commun 320: 1007-1014.
46. Pauli EK, Schmolke M, Wolff T, Viemann D, Roth J, et al. (2008) Influenza A virus inhibits type I IFN signaling via NF-kappaB-dependent induction of SOCS-3 expression. PLoS Pathog 4: e1000196.
47. Shuai K (2006) Regulation of cytokine signaling pathways by PIAS proteins. Cell Res 16: 196-202.
48. Chung CD, Liao J, Liu B, Rao X, Jay P, et al. (1997) Specific inhibition of Stat3 signal transduction by PIAS3. Science 278: 1803-1805.
49. Jacobson NG, Szabo SJ, Weber-Nordt RM, Zhong Z, Schreiber RD, et al. (1995) Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4. J Exp Med 181: 1755-1762.
50. Kusaba H, Ghosh P, Derin R, Buchholz M, Sasaki C, et al. (2005) Interleukin-12-induced interferon-gamma production by human peripheral blood T cells is regulated by mammalian target of rapamycin (mTOR). J Biol Chem 280: 1037-1043.
51. Li Y, Wang X, Douglas SD, Metzger DS, Woody G, et al. (2005) CD8+ T cell depletion amplifies hepatitis C virus replication in peripheral blood mononuclear cells. J Infect Dis 192: 1093-1101.
52. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, et al. (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11: 791-796.
53. Zhang T, Lin RT, Li Y, Douglas SD, Maxcey C, et al. (2005) Hepatitis C virus inhibits intracellular interferon alpha expression in human hepatic cell lines. Hepatology 42: 819-827.
54. Yang JH, Lai JP, Douglas SD, Metzger D, Zhu XH, et al. (2002) Real-time RTPCR for quantitation of hepatitis C virus RNA. J Virol Methods 102: 119-128.